Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASTRO 2022 | 18F-clofarabine as a predictive biomarker for response to DCK-dependent chemotherapeutics

Omar Mian, MD, PhD, Cleveland Clinic, Cleveland, OH, discusses the use of PET imaging as a non-invasive predictive biomarker to allow selection of patient-tailored treatments. 18F-clofarabine (CFA) is a PET radiotracer used to measure deoxycytidine kinase (DCK) activity within a tumour, an enzyme involved in the action of many chemotherapeutics. Dr Mian discusses a study that aims to utilise 18F-clofarabine to determine how a patient will respond to chemotherapy. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.